PTO/SB/81 (09-03)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY and **CORRESPONDENCE ADDRESS INDICATION FORM**

Application Number		10/814,555			
Filing Date		March 30, 2004			
First Nam	ed Inventor	Matthew D. LINNIK			
Title		S OF TREATING AND MONITORING C LUPUS ERYTHEMATOSUS IN ALS			
Art Unit		1645			
Examiner Name		Not Yet Assigned			
Attorney Docket No.		252312008000			

		Atto	orney Docket No.	252312008000)		
I hereby appoint:							
X Practitioners associated with the Customer Number 25226 OR Practitioner(s) named below:							
	Nama	Registration			Registration		
	Name	Number	Name		Number		
as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.							
Please recoo	Please recognize or change the correspondence address for the above-identified application to:						
	ress associated with the	-					
OR							
	ress associated with						
OR Custome	er Number:						
Firm or Individual Name							
Address							
					· · · · · · · · · · · · · · · · · · ·		
City		State		Zip			
Country		Telephone	<u> </u>	Fax			
I am the:							
Applicant	/Inventor.						
	Assignee of record of the entire interest. See 37 CFR 3.71.						
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).							
SIGNATURE of Applicant or Assignee of Record							
Name Andrew Wiseman							
Signature Signature Telephone 858-64/5-66/5							
Date Telephone 858 6 46 - 66 D NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple							
forms if more than one signature is required, see below*.							
X *Total of 1 forms are submitted.							

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)							
Applicant/Patent Owner: Matthew D. LINNIK et al.							
Applicat	ion No./Patent No.:	10/814,555	Filed/Issue Date:	March 30, 2004			
METHODS OF TREATING AND MONITORING SYSTEMIC LUPUS ERYTHEMATOSUS IN INDIVIDUALS							
La Jolla Pharmaceutical Company , a corporation (Name of Assignee) , Type of Assignee, e.g., corporation, partnership, university, government agency, e.g., corporation, government agency, governm							
states th	nat it is:						
1. x the assignee of the entire right, title, and interest; or							
2. an assignee of less than the entire right, title and interest. The extent (by percentage) of its ownership interest is % in the patent application/patent identified above by virtue of either:							
A. [x] An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, or for which a copy thereof is attached.							
OR B. [] A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:							
	1. From:		То:				
			ited States Patent and Trade				
	Reel	, Frame	, or for which a cop	y thereof is attached.			
	2. From:		To:				
	The document was recorded in the United States Patent and Trademark Office at						
	Reel	, Frame	, or for which a cop	y thereof is attached.			
	3. From:		To:	•			
	The document was recorded in the United States Patent and Trademark Office at						
	Reel	, Frame	, or for which a cop	y thereof is attached.			
[] Additional documents in the chain of title are listed on a supplemental sheet.							
[]	Copies of assignme	nts or other documents	in the chain of title are attach	ed.			

[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08] The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee. Andrew Wiseman
Typed or printed name

Signature Senior Director Of Business Development & Investor Relations

Title